E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe respiratory failure in patients with confirmed, suspected or probable Covid- 19 disease |
|
E.1.1.1 | Medical condition in easily understood language |
Patients that are, or may be, infected with the new corona virus and have difficulties breathing. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The overall objective of the study is to evaluate the clinical efficacy and safety of INO compared to standard treatment prior to and during emergency RSI in hypoxic patients with suspected or confirmed COVID-19 |
|
E.2.2 | Secondary objectives of the trial |
*Evaluate the safety of the intervention as compared to the control as assed by: Circulatory function, Kidney function , Hemoglobin function, Platelet count *Evaluate the clinical efficacy of INO compared to standard treatment on respiratory severity and length of specialized care *Evaluate the effect of INO on cardiac stress |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All criteria must apply
Patients ≥ 18 years of age at the time of inclusion
and
who are confirmed, suspected or probable cases of covid-19 based on WHO definitions
and
SpO2 <90% after 3 minutes 10 cm H2O PEEP + 100% O2
and
who are treated by a physician who have specifically undergone formal training in pre-hospital INO administration and the present protocol. |
|
E.4 | Principal exclusion criteria |
Only one criterion needs to apply for exclusion: 1. Patients who after 3 mins of ventilation with 10 cm H2O PEEP + 100% O2 i.e. at time of allocation (t0), have a SpO2 <50%, or a reliable SpO2 is impossible to obtain 2. Patients in severe kidney failure or dialysis, 3. Known or suspected pregnancy based on information on the time of inclusion. 4. Hypersensitivity to the active substance (NO) or to the excipient (N2) 5. Cardiac arrest 6. Patient in prison or custody by police 7. Staff present in treatment situation known to be pregnant 8. Any reason why, in the opinion of the treating physician, it is probably in the best interest of the patient not to participate in the trial.
Female participants under the age of 50 years will be asked explicitly about possible pregnancy. If this cannot be obtained from the patient, next of kin will be asked if present. Information regarding exclusion criteria 2, 3 and 4 will be obtained from bystanders, often relatives or friends present at time of inclusion. If no clear information is available, the physicians shall include or exclude based on his/her best judgment at the time of inclusion.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is the change in SpO2, and the null hypothesis is that there is no difference in the change in SpO2 following initiation of INO |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
five minutes after the allocation of treatment arm, with IMP being administered by bag/mask ventilation, with 100% oxygen at a flow of 10lite/minute and a Positive End Expiratory pressure of 10 centimeter water. |
|
E.5.2 | Secondary end point(s) |
SpO2 during Rapid Sequence Intubation (tRSI)
SpO2 from t1 to End of intervention
Number of patients with SpO2<50 from t1 to End of intervention
Respiratory rate from t0 to tRSI or End of intervention
PaO2 at t0 to End of intervention
Cardiac arrest during intervention
GOS-E score on day 28
Mortality
Secondary
Heart rate at t0-tn
Blood pressure at t0 to tn
Increase in Serum urea concentration
KDIGO AKI Stage up to day 28
Arterial MetHgb concentration
Platelet count
Need for INO after End of intervention
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At specified time point between allocation and end of intervention, which is when inhaled nitric oxide on INOBlender is stopped. Secondary end points also evaluated at day 28 after allocation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |